NA Proactive news snapshot: Zynerba Pharmaceuticals, Nerds On Site, Marvel Discovery, Water Tower Research UPDATE …
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting. The first poster is titled, “Cannabidiol in Fragile X Syndrome (FXS): Proposed Mechanism of Action (MOA) Translates Into Meaningful Clinical Benefits [CONNECT-FX (ZYN2-CL-016)]. The second poster is titled, “A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)].”
About Ayurcann Holdings Corp.
Ayurcann is a leading post-harvest solution provider with a focus on providing and creating custom processes and pharma grade products for the adult use and medical cannabis industry in Canada. Ayurcann is focused on becoming the partner of choice for leading Canadian cannabis brands by providing best-in-class, proprietary services including ethanol extraction, formulation, product development and custom manufacturing.
About Cannmart Inc.
Cannmart provides Canadian medical customers with a diverse selection of hand-picked products from a multitude of federally licensed cultivators. The Company also distributes licensed and in-house branded cannabis and cannabis-derived products in Canada through a number of provincial government control boards and retailing bodies.
NA Proactive news snapshot: Zynerba Pharmaceuticals, Nerds On Site, Marvel Discovery, Water Tower Research UPDATE …
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting. The first poster is titled, “Cannabidiol in Fragile X Syndrome (FXS): Proposed Mechanism of Action (MOA) Translates Into Meaningful Clinical Benefits [CONNECT-FX (ZYN2-CL-016)]. The second poster is titled, “A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)].”